Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Wave Life Sciences Ltd. - Ordinary Shares (NQ:WVE)

8.100 -0.060 (-0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Wave Life Sciences Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
Wave (WVE) Q2 Revenue Drops 56%
Via The Motley Fool
Wave Life Sciences Ltd (NASDAQ:WVE) Reports Q2 2025 Earnings: Revenue Miss but Narrower Loss and Clinical Progress Boost Shares
Wave Life Sciences Q2 2025 results show $8.7M revenue miss but narrower EPS loss. Stock rises on optimism for WVE-006's AATD clinical progress. 
Via Chartmill
Earnings Scheduled For July 30, 2025
 
Via Benzinga
Insights into WAVE Life Sciences's Upcoming Earnings
 
Via Benzinga
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Breaking Down WAVE Life Sciences: 4 Analysts Share Their Views
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
WAVE Life Sciences Earnings Preview
 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
What's Next: WAVE Life Sciences's Earnings Preview
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Where WAVE Life Sciences Stands With Analysts
 
Via Benzinga
The Analyst Verdict: WAVE Life Sciences In The Eyes Of 4 Experts
 
Via Benzinga
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year
Wave Life plans a 2026 NDA filing for WVE-N531 after positive Phase 2 data in Duchenne muscular dystrophy, showing functional gains and biomarker improvements. 
Via Benzinga
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Earnings Scheduled For March 4, 2025
 
Via Benzinga
1 Brand-New Big Reason to Buy This Biotech Stock Right Now
This stock currently has a good balance of risk and potential rewards. 
Via The Motley Fool
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader. 
Via Investor's Business Daily
Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?
These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio? 
Via Benzinga
This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing favorable safety and efficacy in early trial results. GSK holds global license... 
Via Benzinga
Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere
The company is testing its new technology in patients with a genetic disease that impacts the lungs. 
Via Investor's Business Daily
United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
These two could become direct competitors relatively soon. 
Via The Motley Fool
General Motors To $42? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Crude Oil Gains Over 1%; BioVie Shares Plunge
 
Via Benzinga
Nasdaq Surges 100 Points; Thor Industries Earnings Top Views
 
Via Benzinga
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences reveals positive interim data from its Phase 2 FORWARD-53 study on WVE-N531 for Duchenne muscular dystrophy patients. Results show improved muscle health, dystrophin production, and... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.